Double-layer urethral stent with drug carrier

Abstract

The utility model discloses a double -deck urethral support with medicine carrier, including metal support, both ends of metal support are reverse coiling setting, metal support includes inner layer and outer layer, the fixed connection through multiple connecting keys between inner layer and outer layer, be provided with the medicine storage bag in the inner layer, the fixed connection through multiple dissolving keys between medicine storage bag and inner layer, the utility model discloses can increase the support of support, improve the use efficiency of medicine, reduce side effect, and the use effect is better after urethral support installation, and can be to urethral damaged tissue automatic medicine, accelerate the repair of urethra inner wall damaged tissue.

Description

Technical Field

[0001] This utility model relates to the field of urethral stent technology, and in particular to a double-layer urethral stent with a drug carrier. Background Technology

[0002] Urethral stent placement has seen significant development in my country in recent years. The commonly used clinical method is to place a urethral stent at the site of urethral stricture to open up the narrowed or blocked area. This stent is made of stainless steel, synthetic fiber silicone, or nickel-titanium alloy and can be placed at the site of urethral stricture using a cystoscope to expand the previously narrowed and closed posterior urethra. This can restore urination function in most patients with urinary difficulties after the placement of a urethral stent.

[0003] Current urethral stents are all single-layer structures. Due to their relatively weak support capacity, they are prone to deformation and displacement after prolonged use, leading to subsequent complications. Furthermore, existing urethral stents require general anesthesia to reduce patient discomfort during targeted drug delivery, increasing the potential side effects of systemic medication. During stent placement, the urethral wall tissue can be damaged by the stent's friction, requiring a longer healing time and increasing the risk of infection.

[0004] To address this issue, we propose a double-layered urethral stent with a drug carrier. Utility Model Content

[0005] The purpose of this invention is to provide a double-layered urethral stent with a drug carrier to solve the problems mentioned in the background art.

[0006] To achieve the above objectives, this utility model provides the following technical solution:

[0007] A double-layered urethral stent with a drug carrier includes a metal stent, the two ends of which are reverse-curled.

[0008] The metal support includes an inner layer and an outer layer, which are fixedly connected by multiple connecting keys. A drug storage sac is provided inside the inner layer, and the drug storage sac is fixedly connected to the inner layer by multiple dissolution bonds.

[0009] Furthermore, the metal support is covered with a coating layer, which is made of polyethylene glycol diacrylate-based hydrogel material.

[0010] Furthermore, the metal support has a spiral structure and is made of nickel-titanium shape memory alloy.

[0011] Furthermore, the outer surface of the inner layer is covered with a nanofiber network, and the inner layer is made of nickel-titanium shape memory alloy.

[0012] Furthermore, the drug storage bladder is cylindrical in shape, with both ends of the bladder being closed, and the bladder is made of bacterial cellulose membrane.

[0013] Furthermore, multiple connecting bonds are distributed on both sides of the inner layer, and the multiple connecting bonds are arranged in a uniform array. The connecting bonds are made of nickel-titanium shape memory alloy and are integrally formed with the inner and outer layers. Multiple dissolution bonds are evenly distributed on the periphery of the drug storage sac, and the multiple dissolution bonds are arranged in a uniform array on the outside of the drug storage sac. The dissolution bonds are made of bacterial cellulose membrane material.

[0014] Furthermore, multiple coating blocks are fixedly connected to the outer layer, and the multiple coating blocks are distributed in a ring array on the outer layer. The coating blocks are made of bacterial cellulose membrane and are filled with tissue repair drugs.

[0015] Compared with the prior art, the beneficial effects of this utility model are at least as follows:

[0016] 1. By setting up an inner and outer layer, the urethral stent adopts a double-layer design. On the one hand, the double-layer structure can provide stronger support, improve the stability and duration of urethral stent placement, help better maintain the open state of the urethra, and reduce complications caused by stent deformation and displacement. On the other hand, there is a gap between the inner and outer layers of the double-layer structure. After the stent is installed, targeted medication can be directly applied to the designated location through the gap between the inner and outer layers. General anesthesia is not required during medication application, which improves the efficiency of medication and reduces the side effects caused by systemic medication.

[0017] 2. By setting up a drug reservoir, after the urethral stent is installed, the drug reservoir is placed directly in the body. During the subsequent dissolution of the outer wall of the drug reservoir, the drug solution inside the drug reservoir will slowly flow into the urethra for continuous treatment. For a long period of time, there is no need for follow-up examinations and medication, which reduces the time and number of times patients go to the hospital. The effect of urethral stent installation is good.

[0018] 3. By setting up a coating block, after the urethral stent is installed, the coating layer covering it dissolves, and the coating block will directly apply the medicine to the inner wall of the urethra, accelerating the repair of damaged tissues in the inner wall of the urethra.

[0019] This invention can increase the support of the stent, improve the efficiency of medication administration, reduce side effects, and has a good effect after the urethral stent is installed. It can also automatically apply medication to damaged urethral tissue and accelerate the repair of damaged tissue in the urethral wall. Attached Figure Description

[0020] Figure 1 This is a schematic diagram of the structure of this utility model;

[0021] Figure 2 This is a partial structural perspective view of the present invention;

[0022] Figure 3 This is a cross-sectional view of the side structure of this utility model;

[0023] Figure 4 This is a partial structural diagram of the outer layer in this utility model.

[0024] The figure shows: 1. Metal scaffold; 2. Inner layer; 3. Outer layer; 4. Connecting bond; 5. Drug reservoir; 6. Dissolution bond; 7. Covering layer; 8. Coating block; 9. Nanofiber network. Detailed Implementation

[0025] The present invention will now be described in detail with reference to the specific embodiments shown in the accompanying drawings. However, these embodiments do not limit the present invention, and any structural, methodological, or functional modifications made by those skilled in the art based on these embodiments are included within the protection scope of the present invention.

[0026] Please see Figures 1-4 A double-layered urethral stent with a drug carrier includes a metal stent 1, the two ends of which are reverse-curled. Notably, the metal stent 1 has a spiral structure and is made of nickel-titanium shape memory alloy. It should be noted that the spiral structure of the metal stent 1 facilitates the stable fixation of the stent in the urethra and can effectively prevent accidental slippage. This design ensures that the stent can remain firmly in place after implantation, reducing the risk of complications caused by displacement.

[0027] In this invention, the metal support 1 includes an inner layer 2 and an outer layer 3. Furthermore, the outer surface of the inner layer 2 is covered with a nanofiber network 9. It should be noted that the nanofiber network 9 is a mesh material with a porous structure formed by interweaving extremely fine fibers (with a diameter between 1 and 1000 nanometers) together in various ways. These fibers can be natural, synthetic, or inorganic, possessing excellent biocompatibility and biodegradability. The inner layer 2 is made of nickel-titanium shape memory alloy and is fixedly connected to the outer layer 3 by multiple connecting bonds 4. It should be noted that the multiple connecting bonds 4 are distributed on both sides of the inner layer 2 in a uniform array. The connecting bonds 4 are made of nickel-titanium shape memory alloy and are integrally formed with the inner layer 2 and outer layer 3. Multiple dissolving bonds 6 are evenly distributed around the periphery of the drug reservoir 5, forming a uniform array on the outside of the drug reservoir 5. The dissolving bonds 6 are made of bacterial cellulose membrane material. It should be noted that bacterial cellulose membrane has good biocompatibility and biodegradability, and is therefore widely used in the medical field. It can be used as a material for medical supplies such as adhesive bandages, gauze, and hemostatic cotton for wound dressings and burn treatment. Furthermore, it can also be used as artificial skin and artificial blood vessels.

[0028] Through the aforementioned technical features, the urethral stent, with its dual-layer design, provides stronger support, improves the stability and duration of stent placement, helps maintain the urethra's open state, and reduces complications caused by stent deformation and displacement. Furthermore, the gap between the inner and outer layers allows for targeted drug delivery directly to the designated location after stent placement, eliminating the need for general anesthesia and improving drug delivery efficiency while reducing side effects associated with systemic medication.

[0029] In this invention, the inner layer 2, an ideal choice for biomedical materials, is provided with a drug reservoir 5. It should be noted that the drug reservoir 5 is cylindrical in shape, with both ends of the drug reservoir 5 being closed. The drug reservoir 5 is made of bacterial cellulose membrane. The drug reservoir 5 is fixedly connected to the inner layer 2 by multiple dissolution bonds 6. It should be noted that the metal support 1 is covered with a covering layer 7, which is made of polyethylene glycol diacrylate-based hydrogel. It should be noted that multiple coating blocks 8 are fixedly connected to the outer layer 3. The multiple coating blocks 8 are distributed in a ring array on the outer layer 3. The coating blocks 8 are made of bacterial cellulose membrane and are filled with tissue repair drugs.

[0030] With the above-mentioned technical features, after the urethral stent is installed, the drug reservoir 5 is placed directly in the body. During the subsequent dissolution of the outer wall of the drug reservoir 5, the drug solution inside the drug reservoir 5 will slowly flow into the urethra for continuous treatment. For a long period of time, there is no need for follow-up examinations and medication, which reduces the time and number of times patients go to the hospital. The effect of urethral stent installation is good.

[0031] Working principle:

[0032] 1) The urethral stent is delivered into the body and placed in the correct position using a delivery tool. The covering layer 7 is soaked in tissue fluid and dissolved in the body. After dissolution, the nanofiber network 9 continues to dissolve, allowing the internal drug solution to contact the inner wall of the urethra for treatment.

[0033] 2) After the urethral stent is placed in the body for a period of time, the tissue fluid soaks the drug reservoir 5 and the dissolution bond 6, and the drug reservoir 5 and the dissolution bond 6 dissolve. During the dissolution process, the drug solution in the drug reservoir 6 slowly flows into the urethra, providing continuous treatment for the urethra.

[0034] It should be understood that although this specification describes embodiments, not every embodiment contains only one independent technical solution. This way of describing the specification is only for clarity. Those skilled in the art should regard the specification as a whole. The technical solutions in each embodiment can also be appropriately combined to form other implementation methods that can be understood by those skilled in the art.

[0035] The detailed descriptions listed above are merely specific descriptions of feasible implementations of this utility model, and are not intended to limit the scope of protection of this utility model. All equivalent implementations or modifications made without departing from the spirit of this utility model should be included within the scope of protection of this utility model.

Claims

1. A double-layered urethral stent with a drug carrier, characterized in that: include, Metal bracket (1), the two ends of the metal bracket (1) are arranged to be curled in opposite directions; The metal support (1) includes an inner layer (2) and an outer layer (3). The inner layer (2) and the outer layer (3) are fixedly connected by multiple connecting keys (4). A drug storage sac (5) is provided in the inner layer (2). The drug storage sac (5) is fixedly connected to the inner layer (2) by multiple dissolving keys (6).

2. The double-layered urethral stent with a drug carrier according to claim 1, characterized in that: The metal support (1) is covered with a covering layer (7), which is made of polyethylene glycol diacrylate hydrogel material.

3. The double-layered urethral stent with a drug carrier according to claim 1, characterized in that: The metal support (1) has a spiral structure and is made of nickel-titanium shape memory alloy.

4. A double-layered urethral stent with a drug carrier according to claim 1, characterized in that: The outer surface of the inner layer (2) is covered with a nanofiber network (9), and the inner layer (2) is made of nickel-titanium shape memory alloy.

5. A double-layered urethral stent with a drug carrier according to claim 1, characterized in that: The drug storage sac (5) is cylindrical in shape, and both ends of the drug storage sac (5) are closed. The drug storage sac (5) is made of bacterial cellulose membrane.

6. A double-layered urethral stent with a drug carrier according to claim 1, characterized in that: Multiple connecting bonds (4) are distributed on both sides of the inner layer (2). The multiple connecting bonds (4) are arranged in a uniform array. The connecting bonds (4) are made of nickel-titanium shape memory alloy and are integrally formed with the inner layer (2) and the outer layer (3). Multiple dissolution bonds (6) are evenly distributed on the periphery of the drug storage sac (5). The multiple dissolution bonds (6) are arranged in a uniform array on the outside of the drug storage sac (5). The dissolution bonds (6) are made of bacterial cellulose membrane material.

7. A double-layered urethral stent with a drug carrier according to claim 1, characterized in that: Multiple coating blocks (8) are fixedly connected to the outer layer (3). The multiple coating blocks (8) are arranged in a ring array outside the outer layer (3). The coating blocks (8) are made of bacterial cellulose membrane and are filled with tissue repair drugs.

Images